Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new tools for boosting potency and persistence, plus regulatory breakthroughs, to yield a new class of cell therapies.
Quell Therapeutics initiated a Phase 1/2 clinical study (CHILL) of its CAR-Treg therapy QEL-005 for Rheumatoid Arthritis and Systemic Sclerosis, following UK MHRA approval of its Clinical Trial Application.
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling severe immune and inflammatory disease
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling severe immune and inflammatory disease
